Measuring the outcome of clinical trials
Recent articles
Featured articles
Why don’t we have better drugs for autism?
Clinical trials for autism drugs have been plagued with problems: bad design, the wrong measures, too broad a range of participants. All that is finally starting to change.
Why don’t we have better drugs for autism?
Clinical trials for autism drugs have been plagued with problems: bad design, the wrong measures, too broad a range of participants. All that is finally starting to change.
Questions for Gahan Pandina: New tool may aid autism trials
A new ‘knowledge engine’ collects reams of behavioral and sensory data to create highly sensitive outcome measures for autism drugs.
Questions for Gahan Pandina: New tool may aid autism trials
A new ‘knowledge engine’ collects reams of behavioral and sensory data to create highly sensitive outcome measures for autism drugs.
Despite setbacks, fragile X drugs file into clinical trials
Our infographic displays efforts to develop treatments for fragile X syndrome. So far, none of them have passed muster in clinical trials.
Despite setbacks, fragile X drugs file into clinical trials
Our infographic displays efforts to develop treatments for fragile X syndrome. So far, none of them have passed muster in clinical trials.
From the archives
The innovators: How families launch their own autism studies
Some parents are starting ‘N-of-1’ studies for autism, but their efforts don’t always get taken seriously.
The innovators: How families launch their own autism studies
Some parents are starting ‘N-of-1’ studies for autism, but their efforts don’t always get taken seriously.
Questions for James McPartland: Biomarkers for better trials
A $28 million initiative aims to develop objective tools for tracking social skills in children with autism. The initiative’s leader outlines its approach.
Questions for James McPartland: Biomarkers for better trials
A $28 million initiative aims to develop objective tools for tracking social skills in children with autism. The initiative’s leader outlines its approach.
Devising spectrum of tests for different types of autism
Finding biomarkers for different forms of autism may lead to more effective treatments for each.
Devising spectrum of tests for different types of autism
Finding biomarkers for different forms of autism may lead to more effective treatments for each.
Better behavioral tests may save trials of autism treatments
Trials to test drugs for autism suffer from subjective measurements and placebo effects. Helen Tager-Flusberg outlines how to ferret out the true effects of potential autism therapies.
Better behavioral tests may save trials of autism treatments
Trials to test drugs for autism suffer from subjective measurements and placebo effects. Helen Tager-Flusberg outlines how to ferret out the true effects of potential autism therapies.
Some people in ‘failed’ drug trial for autism showed benefit
An experimental drug called arbaclofen improved autism features in about 13 percent of people who took it in a shuttered clinical trial.
Some people in ‘failed’ drug trial for autism showed benefit
An experimental drug called arbaclofen improved autism features in about 13 percent of people who took it in a shuttered clinical trial.
Questions for Eric Klann: Translating treatments for fragile X
Treatments for fragile X syndrome may be more successful if they block direct targets of the key missing protein, says Eric Klann.
Questions for Eric Klann: Translating treatments for fragile X
Treatments for fragile X syndrome may be more successful if they block direct targets of the key missing protein, says Eric Klann.
Why trials of autism treatments have a placebo problem
People with autism — and their family members — are susceptible to powerful placebo effects. Some researchers are using the problem to better understand this mystifying phenomenon.
Why trials of autism treatments have a placebo problem
People with autism — and their family members — are susceptible to powerful placebo effects. Some researchers are using the problem to better understand this mystifying phenomenon.
Questions for Elizabeth Berry-Kravis: Measuring drug effects
Drugs designed to treat fragile X syndrome have yet to show substantial benefits in people. But rather than abandon them, child neurologist Elizabeth Berry-Kravis suggests a new way to measure their effectiveness.
Questions for Elizabeth Berry-Kravis: Measuring drug effects
Drugs designed to treat fragile X syndrome have yet to show substantial benefits in people. But rather than abandon them, child neurologist Elizabeth Berry-Kravis suggests a new way to measure their effectiveness.
Better tools needed to assess clinical trials
The past few years have seen an unprecedented number of clinical trials for experimental drugs to treat autism-related disorders, most notably for fragile X syndrome. But as the trials progress, scientists are calling for better methods to measure the drugs’ effectiveness.
Better tools needed to assess clinical trials
The past few years have seen an unprecedented number of clinical trials for experimental drugs to treat autism-related disorders, most notably for fragile X syndrome. But as the trials progress, scientists are calling for better methods to measure the drugs’ effectiveness.
Explore more from The Transmitter
Waves of calcium activity dictate eye structure in flies
Synchronized signals in non-neuronal retinal cells draw the tiny compartments of a fruit fly’s compound eye into alignment during pupal development.
Waves of calcium activity dictate eye structure in flies
Synchronized signals in non-neuronal retinal cells draw the tiny compartments of a fruit fly’s compound eye into alignment during pupal development.
Among brain changes studied in autism, spotlight shifts to subcortex
The striatum and thalamus are more likely than the cerebral cortex to express autism variants or bear transcriptional changes, two unpublished studies find.
Among brain changes studied in autism, spotlight shifts to subcortex
The striatum and thalamus are more likely than the cerebral cortex to express autism variants or bear transcriptional changes, two unpublished studies find.
What is the future of organoid and assembloid regulation?
Four experts weigh in on how to establish ethical guardrails for research on the 3D neuron clusters as these models become ever more complex.
What is the future of organoid and assembloid regulation?
Four experts weigh in on how to establish ethical guardrails for research on the 3D neuron clusters as these models become ever more complex.